par Cailleux, Frédéric 
;Agostinetto, Elisa;Lambertini, Matteo ;Rothé, Françoise ;Wu, Hsin-Ta;Balcioglu, Mustafa;Kalashnikova, Ekaterina;Vincent, Delphine;Viglietti, Giulia ;Gombos, Andrea ;Papagiannis, Andreas ;Veys, Isabelle;Awada, Ahmad;Sethi, Himanshu;Aleshin, Alexey;Larsimont, Denis ;Sotiriou, Christos ;Venet, David ;Ignatiadis, Michail
Référence JCO Precision Oncology, 6, page (e2200148)
Publication Publié, 2022-09-01
;Agostinetto, Elisa;Lambertini, Matteo ;Rothé, Françoise ;Wu, Hsin-Ta;Balcioglu, Mustafa;Kalashnikova, Ekaterina;Vincent, Delphine;Viglietti, Giulia ;Gombos, Andrea ;Papagiannis, Andreas ;Veys, Isabelle;Awada, Ahmad;Sethi, Himanshu;Aleshin, Alexey;Larsimont, Denis ;Sotiriou, Christos ;Venet, David ;Ignatiadis, Michail Référence JCO Precision Oncology, 6, page (e2200148)
Publication Publié, 2022-09-01
Article révisé par les pairs
| Résumé : | Detection of circulating tumor DNA (ctDNA) after neoadjuvant chemotherapy in patients with early-stage breast cancer may allow for early detection of relapse. In this study, we analyzed ctDNA using a personalized, tumor-informed multiplex polymerase chain reaction-based next-generation sequencing assay. |
